Literature DB >> 32094835

A rude awakening from tumour cells.

Fatima Cardoso, Giuseppe Curigliano.   

Abstract

Entities:  

Keywords:  Cancer; Health care; Medical research

Year:  2018        PMID： 32094835     DOI： 10.1038/d41586-018-01140-z

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  7 in total

Review 1.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

2.  Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.

Authors:  Marco Colleoni; Zhuoxin Sun; Karen N Price; Per Karlsson; John F Forbes; Beat Thürlimann; Lorenzo Gianni; Monica Castiglione; Richard D Gelber; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

3.  20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Authors:  Hongchao Pan; Richard Gray; Jeremy Braybrooke; Christina Davies; Carolyn Taylor; Paul McGale; Richard Peto; Kathleen I Pritchard; Jonas Bergh; Mitch Dowsett; Daniel F Hayes
Journal:  N Engl J Med       Date:  2017-11-09       Impact factor: 91.245

4.  The genomic landscape of breast cancer as a therapeutic roadmap.

Authors:  Matthew J Ellis; Charles M Perou
Journal:  Cancer Discov       Date:  2013-01       Impact factor: 39.397

5.  Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Authors:  Paul E Goss; James N Ingle; Kathleen I Pritchard; Nicholas J Robert; Hyman Muss; Julie Gralow; Karen Gelmon; Tim Whelan; Kathrin Strasser-Weippl; Sheldon Rubin; Keren Sturtz; Antonio C Wolff; Eric Winer; Clifford Hudis; Alison Stopeck; J Thaddeus Beck; Judith S Kaur; Kate Whelan; Dongsheng Tu; Wendy R Parulekar
Journal:  N Engl J Med       Date:  2016-06-05       Impact factor: 91.245

6.  Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Marco Colleoni; Weixiu Luo; Per Karlsson; Jacquie Chirgwin; Stefan Aebi; Guy Jerusalem; Patrick Neven; Erika Hitre; Marie-Pascale Graas; Edda Simoncini; Claus Kamby; Alastair Thompson; Sibylle Loibl; Joaquín Gavilá; Katsumasa Kuroi; Christian Marth; Bettina Müller; Seamus O'Reilly; Vincenzo Di Lauro; Andrea Gombos; Thomas Ruhstaller; Harold Burstein; Karin Ribi; Jürg Bernhard; Giuseppe Viale; Rudolf Maibach; Manuela Rabaglio-Poretti; Richard D Gelber; Alan S Coates; Angelo Di Leo; Meredith M Regan; Aron Goldhirsch
Journal:  Lancet Oncol       Date:  2017-11-17       Impact factor: 41.316

7.  Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers.

Authors:  Daniela Tosoni; Sarah Pambianco; Blanche Ekalle Soppo; Silvia Zecchini; Giovanni Bertalot; Giancarlo Pruneri; Giuseppe Viale; Pier Paolo Di Fiore; Salvatore Pece
Journal:  EMBO Mol Med       Date:  2017-05       Impact factor: 12.137
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.